The 3.75 mg formulation is commonly used across conditions presenting with systemic or localized discomfort. This medication is commonly used to help patients cope with the overall symptomatic burden across several critical areas, particularly those characterized by systemic imbalance. This treatment is applied in scenarios where additional management of discomfort is required.

Main Therapeutic Domains and Benefits

The 3.75 mg formulation is applied across domains where additional symptomatic support is needed. This treatment is generally used during phases when symptoms become more noticeable and is relevant for easing symptoms related to physical discomfort and those that interfere with daily functioning. The overall goal is to provide supportive relief that helps patients cope more steadily with symptom fluctuations.

“It helps address symptom clusters that may become intense or disruptive, and assists with maintaining functional stability.”

Symptomatic Relief and Stability

This therapeutic approach is relevant when supportive symptom management is appropriate in clinical settings involving acute or unstable symptom patterns. The treatment contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Quick Fact: Support for Symptom Clusters
Diphereline 3.75 mg is often used when symptoms cluster into patterns requiring supportive management, helping maintain a sense of stability when symptoms are more noticeable.

Diphereline 3.75 mg is officially contraindicated (must not be used) in patients with known hypersensitivity to the active ingredient Triptorelin, other GnRH agonists, or any component of the injection. Its use is strictly prohibited in pregnant women and breastfeeding women due to the drug's hormonal effects.

Age and Condition Restrictions

Eligibility is established in adult men with advanced prostate cancer and in children ge 2 years of age for Central Precocious Puberty (CPP). For men, the medicine must not be used if the prostate tumor is not hormone-dependent or if they have undergone surgical castration. No dosage adjustment is officially required for patients with renal or hepatic impairment.

Conditional Use and Monitoring

The official labeling mandates close monitoring for certain populations. Patients with pre-existing cardiovascular risk factors, diabetes, or a history of depression must be carefully observed. CPP treatment must be stopped when bone maturation age reaches specified limits (e.g., 13-14 years for boys). Women of childbearing potential are required to use effective non-hormonal contraception throughout the course of therapy.

Interactions with other medicines and products

The interaction profile of Diphereline 3.75 mg (Triptorelin) is characterized by specific pharmacodynamic cautions and mandated timing rules, as documented in official regulatory sources. The medicine is classified as an Androgen Deprivation Therapy (ADT) which carries documented interaction risks.

Pharmacodynamic Interaction

The primary drug-drug interaction caution involves co-administration with other medicinal products known to prolong the QT interval. The official labeling states that Triptorelin itself may prolong the QT interval, requiring a clinical risk assessment before co-administering with other agents that have a similar effect on cardiac rhythm.

Pharmacokinetic and Metabolic Profile

Official regulatory information reports that Triptorelin metabolism is unlikely to involve hepatic microsomal enzymes (CYP P-450), indicating that it is not expected to cause or be subject to drug interactions mediated by this pathway. However, due to the involvement of the liver and kidneys in its clearance, plasma exposure (AUC) is officially documented to be increased in subjects with renal or liver insufficiency.

Mandatory Timing Rules

For specific therapeutic applications, the official labeling includes mandatory timing constraints: Triptorelin treatment must be initiated at least six to eight weeks (a minimum of two injections) before starting Aromatase Inhibitor treatment when used in combination for hormone-sensitive breast cancer.

Interaction with Diagnostic Procedures

Administration of this medicine results in suppression of the pituitary-gonadal axis. Consequently, diagnostic tests of this function conducted during treatment or shortly after the cessation of therapy may yield misleading results.

Diphereline, containing triptorelin, is a synthetic gonadotropin-releasing hormone (GnRH) decapeptide analog.

Following initial administration, triptorelin acts as a superagonist at the GnRH receptors located on the plasma membranes of the gonadotroph cells in the anterior pituitary gland.

This initial, high-affinity agonist binding and prolonged stimulation trigger a phase of acute, enhanced secretion of the gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), known as the "flare-up" effect.

However, the continuous, non-pulsatile presence of high concentrations of triptorelin leads to a rapid desensitization and downregulation of the pituitary GnRH receptors. This is achieved through receptor internalization and modification of intracellular signaling pathways, specifically the Gq protein-coupled signaling cascade.

The sustained downregulation of GnRH receptors effectively blocks the pituitary's response to endogenous GnRH. Consequently, the output of both LH and FSH is significantly suppressed (hypogonadotropic state). This suppression, in turn, leads to a profound reduction in the systemic secretion of gonadal sex steroids, namely testosterone in males and estradiol in females, resulting in a systemic physiological state analogous to surgical castration.

How to Use Diphereline 3.75 mg (Triptorelin Depot)

The instructions for Diphereline 3.75 mg establish its use as a standardized, fixed-dose, fixed-interval injection, administered in a professional healthcare setting. The medication is supplied as a powder and solvent that must be reconstituted only with the supplied solvent to form a suspension. This suspension must be injected immediately after preparation to ensure correct delivery of the prolonged-release properties.

Official Administration Guidelines

Feature	Instruction
Route of Administration	Intramuscular (IM) or Subcutaneous (SC) injection, performed by a healthcare professional.
Standard Adult Dosing	A single injection of 3.75 mg of Triptorelin is administered.
Dosing Frequency	The standard frequency is once every 4 weeks (28 days). Strict adherence to this interval is required to maintain consistent hormonal suppression.
Special Use Initiation	For female reproductive conditions, administration must be initiated within the first five days of the menstrual cycle.
Duration Patterns	Treatment is typically long-term for prostate carcinoma. For conditions like endometriosis or uterine fibroids, treatment duration is often limited to no more than 6 months.

Population-Specific Use

Dosage adjustments are generally not required for older adults or patients with renal or hepatic impairment. For pediatric use in central precocious puberty, the dose of 3.75 mg is used for children weighing over 30 kg, but lower doses are employed for lighter children, demonstrating a weight-dependent protocol.

Procedural Context

The injection site must be alternated periodically, and the suspension must be checked to be homogeneous (milky-white to faintly yellow) before administration. If a dose is missed or delayed, the patient must contact their healthcare professional immediately to reschedule and prevent treatment disruption.

Research Evidence / Overview of Studies for Diphereline 3.75 mg

Evidence for Use in Advanced Hormone-Dependent Prostate Cancer

Research for this indication includes Randomized Controlled Trials (RCTs) and non-comparative trials applied in adult men. Studies primarily examined the ability to achieve and maintain castrate serum testosterone levels over the study period, reporting patterns related to this goal. Researchers also described changes in the biomarker Prostate Specific Antigen (PSA). Long-term effects regarding non-hormonal quality-of-life metrics beyond specific symptoms are not fully established across all published findings.

Evidence for Use in Endometriosis

The evidence base includes Multicenter Clinical Trials and Prospective Observational Studies applied in research examining short-term symptom patterns in premenopausal women. Studies observed the suppression of sex hormones (Estradiol) and tracked patient-reported outcomes describing perceived discomfort. Findings described patterns where studies reported how symptoms evolved during the study period. The optimal duration of treatment remains a focus of research, especially considering the necessary short duration due to potential effects on bone health.

Evidence for Use in Central Precocious Puberty (CPP)

Research designs included Long-term Observational Studies and efficacy trials monitoring children (predominantly girls before age 8 and boys before age 9). Key measured endpoints involved the suppression of pubertal hormones (LH and FSH) and tracking of auxological outcomes such as predicted adult height. Studies consistently described a pattern of rapid suppression of the pituitary-gonadal axis, resulting in pubertal hormone levels returning to prepubertal norms. Research is ongoing to refine the findings regarding long-term outcomes relative to children who are not treated.

Research Gaps and Follow-up Durations

Clinical follow-up durations vary by indication. For prostate cancer, tracking is intermediate (6 to 12 months); for endometriosis, treatment is limited to a maximum of six months with post-therapy follow-up (6 to 24 months). Long-term effects are not fully established across all indications. Data for certain subgroups remain insufficient, and comparative evidence is lacking in some areas. Research findings describe group patterns and do not determine whether an individual will respond similarly.

Common questions about Diphereline 3.75 mg (FAQ)

---

Q: How quickly does Diphereline 3.75 mg start to work?

A: The medicine begins acting immediately upon injection, causing a temporary surge in hormones known as the flare effect. A sustained, desired reduction of sex hormones is generally observed following this initial phase, according to clinical goals. Regulatory documents suggest that the goal of hormone suppression is usually achieved within 2 to 4 weeks after the first injection.

---

Q: Is the Diphereline 3.75 mg injection painful?

A: According to official documentation, side effects commonly reported include temporary pain, redness, swelling, or bruising at the injection site. This type of localized discomfort is documented as a common reaction associated with the administration process.

---

Q: What is the general duration of treatment with Diphereline 3.75 mg?

A: The required duration of treatment varies based on the medical condition being managed. For prostate cancer, the treatment is typically administered long-term or indefinitely. For conditions such as endometriosis or uterine fibroids, treatment is often limited to a duration of no more than 6 months.

---

Q: Can Diphereline 3.75 mg cause changes in bone density?

A: Yes. Due to the hormone-suppressing effect, official safety information indicates that long-term exposure to Triptorelin is associated with a risk of decreased bone mineral density. For non-cancer conditions, official treatment duration may be limited due to the documented potential for changes in bone density.

---

Q: Does Diphereline 3.75 mg have an impact on sexual function?

A: Official product information for men lists reduced libido (sex drive) and impotence (erectile dysfunction) as very common side effects. These reported effects are consistent with the medicine's primary action of reducing systemic hormone levels.

---

Q: Can Diphereline 3.75 mg affect blood sugar levels?

A: Triptorelin may be associated with an increased risk of developing diabetes mellitus in men, as noted in regulatory warnings. Official labeling states that careful monitoring of blood sugar levels may be necessary for patients with pre-existing diabetes while using the medicine.

---

Q: Do official sources discuss the possibility of allergic reactions to Diphereline 3.75 mg?

A: Yes, official documents address allergic reactions. Hypersensitivity to the drug or its components is listed as a contraindication (a reason not to use the drug). Rare, severe allergic reactions, such as anaphylactic reaction, and other skin reactions like hives have also been reported.

---

Q: What is the difference between Diphereline and other similar injections?

A: Diphereline belongs to the general class of GnRH agonists. While the active ingredient, Triptorelin, is the same, the main differences are often related to the formulation and the release profile of the injection. Diphereline 3.75 mg is designed to be a prolonged-release formulation, maintaining drug levels over a one-month period.

---

Q: Is weight gain a possible side effect of Diphereline 3.75 mg?

A: Yes. Official documentation confirms that weight gain is a common side effect associated with the use of Diphereline. This effect is consistent with the hormonal shifts the treatment is designed to induce.

---

Q: What happens if a person misses a scheduled dose of Diphereline 3.75 mg?

A: Missing or delaying a scheduled dose prevents the medicine from maintaining consistent hormonal suppression in the body. If an injection is missed, official instructions emphasize the need to contact a healthcare professional immediately to reschedule and help ensure consistent treatment effect is maintained.

---

Q: Is Diphereline 3.75 mg used in children?

A: Yes. Triptorelin is officially indicated for use in children aged 2 years and older who have been diagnosed with Central Precocious Puberty (CPP). This use is for the specific purpose of suppressing premature puberty.

---

Q: Are there any foods or drinks to avoid while taking Diphereline 3.75 mg?

A: Official patient information notes that alcohol consumption and stimulants should generally be avoided or limited during treatment. If the patient experiences side effects such as dizziness or light-headedness, official warnings note that alcohol may potentially make these feelings worse.

---

Q: Is it safe to take Diphereline 3.75 mg with blood pressure medication?

A: Due to the potential for the medicine to affect blood pressure, it is important to ensure the prescribing healthcare professional is aware of all medicines being taken to lower blood pressure, allowing for appropriate monitoring.

---

Q: Is it normal to feel tired after receiving Diphereline 3.75 mg?

A: Yes. Tiredness or weakness (asthenia) is commonly reported in official adverse reaction documents. These feelings are noted as a common side effect of the treatment itself.

---

Q: What should be done if there is a reaction at the injection site?

A: While minor pain, redness, or swelling at the injection site are common, any persistent, severe, or worsening reaction should be brought to the attention of a healthcare professional. Severe allergic reactions also require immediate professional attention.

---

Q: Does Diphereline 3.75 mg have any restrictions regarding driving or operating machinery?

A: Official documentation advises caution regarding driving or operating machinery if the patient experiences side effects such as dizziness, light-headedness, blurred vision, or seizures. These potential effects may temporarily impair judgment or coordination.

---

Q: Is the use of Diphereline 3.75 mg reversible?

A: Yes, for many non-cancer conditions, the effects are intended to be temporary. In children treated for CPP, for example, puberty is expected to resume after the treatment is stopped. The medicine is generally understood to provide a temporary, reversible chemical suppression of hormone production for many non-cancer uses.

---

Q: Are there any specific laboratory tests needed during treatment with Diphereline 3.75 mg?

A: Yes. Patients are typically monitored with specific laboratory tests, such as monitoring serum testosterone and PSA levels in men. Additionally, monitoring of blood sugar, cardiovascular parameters, and bone density may be necessary, particularly during long-term treatment.

---

Q: What information is available about Diphereline 3.75 mg and alcohol consumption?

A: Official patient information notes that alcohol consumption and stimulants should generally be avoided. If the patient experiences side effects like dizziness or light-headedness, official warnings note that consuming alcohol may potentially make these feelings worse.

---

Q: Is Diphereline 3.75 mg used for sex hormone-related conditions?

A: Yes. The fundamental therapeutic purpose of this drug is to reduce the systemic levels of sex hormones, such as testosterone and estradiol, by suppressing the pituitary gland. It is therefore utilized for conditions that are sensitive to these hormones.

---

Q: How does Diphereline 3.75 mg work differently for men vs. women?

A: The mechanism of action is the same in both men and women: it suppresses the pituitary-gonadal axis. The practical difference is the primary hormone being suppressed. In men, it profoundly reduces testosterone levels, and in women, it profoundly reduces estradiol (estrogen) levels.

---

Q: Can Diphereline 3.75 mg be used if a patient has a history of heart problems?

A: Patients with a history of heart or vascular problems or other major cardiovascular risk factors must be carefully monitored. Official warnings note that this is due to an increased risk of cardiovascular events and the possibility that the drug may prolong the QT interval.

How to Store and Dispose of Diphereline 3.75 mg

Official regulatory documentation strictly defines the storage and disposal requirements for Diphereline 3.75 mg to ensure product stability and safety. The unopened powder and solvent must be kept out of the sight and reach of children and stored in the original container.

Storage and Stability Constraints

Requirement	Specific Condition
Temperature	Store below 25 C in a cool, dry place. Do not freeze.
Post-Reconstitution	The suspension must be administered immediately after mixing and discarded if not used right away (single-use only).

Disposal Requirements

Used injection needles and syringes must be placed into a designated puncture-proof sharps container. All unused medicine and waste materials must be disposed of according to local requirements and official pharmaceutical waste handling procedures.